Comparison of tumour markers in malignant
|
|
|
- Quentin Phelps
- 10 years ago
- Views:
Transcription
1 Thorax 1985;40:91-95 Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma AR GIBBS, R HARACH, JC WAGNER, B JASANI From the Pathology Department, Welsh National School, Cardiff, and the Medical Research Council Pneumoconiosis Unit, Llandough Hospital, Penarth, Glamorgan ABSTRACr Immunohistological methods were used to investigate the presence of carcinoembryonic antigen,,31 pregnancy specific glycoprotein, /8 subunit of human chorionic gonadotrophin, human placental lactogen, calcitonin, and keratin in formalin fixed tissue from 29 malignant mesotheliomas and 27 pulmonary adenocarcinomas. Malignant mesotheliomas were negative for tumour markers except for the,8 subunit of human chorionic gonadotrophin and keratin, one and 13 cases respectively being positive for these. Pulmonary adenocarcinomas, however, were frequently positive for tumour markers-namely, carcinoembryonic antigen (24),,3B pregnancy specific glycoprotein (23),,8 subunit of human chorionic gonadotrophin (8), human placental lactogen (2), calcitonin (3), and keratin (12). The presence of carcinoembryonic antigen and,/3 pregnancy specific glycoprotein within an intrathoracic tumour is strong evidence against its being of mesothelial origin. The accurate diagnosis of malignant tumours is an essential part of the management of patients, but for some tumours it can still pose many problems. One particularly difficult and important problem is the separation of malignant mesothelioma from pulmonary adenocarcinoma-difficult because these tumours may closely resemble each other in their pattern of spread and their microscopic appearances,' 2 and important not only for clinical management but also for reasons of industrial compensation. Many attempts have been made to provide an easily used technique which gives a clear separation between the two tumours. Mucin histochemistry has been used, positive staining of tumour cells for hyaluronic acid favours a diagnosis of malignant mesothelioma, whereas the presence of neutral mucin is indicative of adenocarcinoma.34 This technique is not, however, widely used, partly because not every adenocarcinoma contains neutral mucin, but also because the preservation of intracellular hyaluronic acid requires special fixative methods. Ultrastructural features can also be used to distinguish these two tumours.5 Here too the problem Address for reprint requests: Dr AR Gibbs, Pathology Department, Welsh National School of Medicine, Cardiff CF4 4XN. Accepted 3 September 1984 needs to be recognised well in advance, so that the appropriate fixation and embedding techniques can be used. The introduction of immunocytochemical techniques into routine pathological diagnosis has led to improvement in tumour diagnosis generally; in the differential diagnosis of malignant mesothelioma and adenocarcinoma reports have been conflicting. Antibodies to carcinoembryonic antigen and keratin have been used, and it has been claimed that carcinoembryonic antigen is frequently present in pulmonary adenocarcinoma but almost invariably absent in malignant mesothelioma.6-9 Keratin proteins are found by some workers to be frequently present in malignant mesothelioma and absent in pulmonary adenocarcinoma,9 10 while others have found positive keratin staining in pulmonary adenocarcinoma also." 12 In a previous study of lung tumours using immunocytochemical techniques we studied various antigens and found that immunoreactive carcinoembryonic antigen was present in 71%, /,3 pregnancy specific glycoprotein (SP,) in 68%,,3 subunit of human chorionic gonadotrophin (,3HCG) in 36%, human placental lactogen in 20%, and calcitonin in 14%.'3 Because of the conflicting results of other studies in the separation of pulmonary adenocarcinoma and mesothelioma, we have applied these five antibodies together with a keratin 91
2 92 antibody to a new series of 56 pulmonary tumours to define which investigations are likely to be of value in this important differential diagnosis. Methods Sections (5,um thick) were taken from formalin fixed, conventionally processed paraffin embedded material. Twenty nine malignant mesotheliomas and 27 pulmonary adenocarcinomas were studied. The malignant mesotheliomas were all from necropsy cases with typical macroscopic and microscopic appearances and without any other probable primary source; they comprised 12 purely epithelial tumours, 14 mixed epithelial and sarcomatous tumours, and three purely sarcomatous tumours. Histochemical staining for neutral mucin (periodicacid-schiff diastase technique'4) was negative for each malignant mesothelioma. The pulmonary adenocarcinomas were from both surgical (13) and necropsy (14) cases: six were well differentiated, three moderately differentiated, and 11 poorly differentiated; three were solid tumours with mucin content, one was a bronchioloalveolar carcinoma, and three were adenosquamous carcinomas. The six immunohistological markers were localised by a modification of the DPN-hapten staining techniques,'5 16 the following dilutions and incubation times being used: (1) carcinoembryonic antigen (Dakopatts), 1:2000 for 15 hours; (2),f3 pregnancy specific glycoprotein (Dakopatts), 1:1600 for 15 hours; (3) keratin (Miles-Yeda), 1:200 for 15 hours; (4) 18 subunit of human chorionic gonadotrophin (Dakopatts), 1:400 for 15 hours; (5) human placental lactogen (Dakopatts), 1:800 for 15 hours; (6) calcitonin 1:200 for 15 hours. Prior trypsinisation'7 was carried out for one hour for calcitonin and four hours for 1, pregnancy specific glycoprotein, the,8 subunit of human chorionic Gibbs, Harach, Wagner, Jasani gonadotrophin, and human placental lactogen. Trypsinisation was not performed for carcinoembryonic antigen or keratin. Appropriate positive and negative controls were included with each batch of staining. The dilutions and incubation times were selected as those which gave consistently good staining with a clear background in an appropriate positive control tissue. These were slightly modified from those used in our previous study for consistency and greater reliability.'3 The degree of staining for the appropriate antigen was graded for each tumour as follows: 0-negative; + (weak)-less than 5% of the tumour cells intensely or moderately stained; + + (moderate)- 5-33% of the tumour cells intensely or moderately stained; (strong)-more than 33% of the tumour cells intensely or moderately stained. Results The results of staining for each tumour marker are shown in the table. Carcinoembryonic antigen was present in 24 out of 27 adenocarcinomas tested but absent in all the malignant mesotheliomas. The tumour product of diaminobenzidine was located predominantly along the luminal surfaces of the tumour cells but it was also seen to a lesser extent in both diffuse and granular patterns within the cytoplasm of the tumour cells, particularly in the less well differentiated adenocarcinomas, but this was not statistically significant. Two of the three adenosquamous carcinomas showed moderate staining for carcinoembryonic antigen; there was staining of both the glandular and the squamous elements, the latter being mainly located along cell membranes and within epithelial pearls. Staining for 13, pregnancy specific glycoprotein was positive in 23 of 27 adenocarcinomas but negative in all malignant mesotheliomas tested. There Results ofimmunostaining for the six tumour markers Tumour Histological Degree ofpositvity* Total marker type of tumour Carcinoembryonic antigen Adenocarcinoma Mesothelioma ,(, pregnancy specific glycoprotein Adenocarcinoma Mesothelioma The beta subunit of human chorionic Adenocarcinoma gonadotrophin Mesothelioma Human placental lactogen Adenocarcinoma Mesothelioma Calcitonin Adenocarcinoma Mesothelioma Keratin Adenocarcinoma Mesothelioma *(}negative; +-<5% of tumour cells intensely or moderately stained; % of cells intensely or moderately stained; >33% of cells intensely or moderately stained.
3 Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma was no correlation between the histological differentiation of the adenocarcinomas and the degree of positivity. The pattern of staining was similar to that of carcinoembryonic antigen, being strongest along the luminal border of the cells but also present within the cytoplasm in diffuse and granular patterns. Two of the three adenosquamous carcinomas showed weak staining in both the glandular and the squamous components. The latter showed staining of the cell borders and epithelial pearls. It is noteworthy that staining for either carcinoembryonic antigen or fl, pregnancy specific found positivity in glycoprotein or both was positive in all adenocinoembryonic antigen is carcinomas but was negative for both in all malignant mesotheliomas. Weak positive staining for the f3 subunit of human chorionic gonadotrophin was observed in eight of 25 adenocarcinomas and one of 27 malignant mesotheliomas. The staining was predominantly intracytoplasmic in diffuse or granular patterns. Weak positive diffuse intracytoplasmic staining for human placental lactogen was seen in two of 25 adenocarcinomas, while it was negative in all 27 malignant mesothelioma. Staining for calcitonin was weakly positive in three of 25 adenocarcinomas; the three positives comprised a solid carcinoma with mucin content, a poorly differentiated acinar adenocarcinoma, and a moderately differentiated papillary adenocarcinoma. It was negative in all 27 malignant mesotheliomas. Positive staining for keratin was observed in 12 of 27 adenocarcinomas and in 13 of 29 malignant mesotheliomas, but there was no direct correlation with differentiation. In the adenocarcinomas staining was seen predominantly at the periphery of the cells. The malignant mesotheliomas showed mainly diffuse intracytoplasmic staining, present in both epithelial and sarcomatous areas but more prevalent in the former. There appeared to be no significant differences in the staining of any one marker between necropsy and surgical tissues. Discussion 93 Our study clearly shows that the use of immunolocalisation procedures for certain antigens is a valuable adjunct in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. The most useful in this respect appear to be carcinoembryonic antigen and f3, pregnancy specific glycoprotein. Our findings of carcinoembryonic antigen in 89% of adenocarcinomas and in none of the malignant mesotheliomas accords with those of other investigators. Wang et a16 found carcinoembryonic antigen positivity in all 12 pulmonary adenocarcinomas tested but in none of nine malignant mesotheliomas. Whitaker et al' found positivity in 22 of 26 pulmonary adenocarcinomas and in none of 43 malignant mesotheliomas. Corson and Pinkus,8 however, found weak staining in eight and moderate staining in one of 20 malignant mesotheliomas, whereas they found that all adenocarcinomas exhibited strong or moderate staining. Pascal et al'8 16 of 22 adenocarcinomas. We conclude that a positive immunoreaction for car- strong evidence against a mesothelial origin for a primary intrathoracic tumour. The so called trophoblast specific pregnancy proteins-/3, pregnancy specific glycoprotein, the beta subunit of human chorionic gonadotrophin and human placental lactogen, normally synthesised by the human placenta-have now been demonstrated by immunolocalisation procedures in tissue sections of certain non-trophoblastic as well as trophoblastic tumours.' A few studies have reported raised serum concentrations of various placental proteins in a small proportion of patients with lung carcinomas Wilson et a124 investigated the beta subunit of human chorionic gonadotrophin in tissue sections from 61 lung tumours and found positive staining in 84%. In a previous study using immunolocalisation procedures we showed /,3 pregnancy specific glycoprotein in 68%, the beta subunit of human chorionic gonadotrophin in 36%, and placental lactogen in 20%.'3 The present study of a separate group of tumours shows that pulmonary adenocarcinomas are frequently positive for f,3 pregnancy specific glycoprotein (85%), less frequently for the beta subunit of human chorionic gonadotrophin (32%), and positive for placental lactogen in only 12%. There was no direct relationship between the presence of one placental protein and the presence of another. With the exception of a case of that showed weak staining for the beta subunit of human chorionic gonadotrophin, malignant mesotheliomas appeared uniformly negative for each of the placental proteins studied. Immunohistological investigation of placental proteins in malignant mesotheliomas has not previously been reported and our results show that the presence of a positive immunoreaction of 8, pregnancy specific glycoprotein is again strong evidence against a mesothelial origin for a primary intrathoracic tumour. Raised levels of calcitonin have been described in various lung tumours25-26 but few immunohistological studies have reported. Calcitonin positive cells have been described in some bronchial car-
4 94 cinoids, small cell carcinomas, and adenocarcinomas of lung.' The present study showed weak positivity in 12% of pulmonary adenocarcinomas. All malignant mesotheliomas were negative. Previous results for keratin staining in adenocarcinomas have been conflicting. Corson and Pinkus8 stated that staining for keratin was weak or negative in 18/20 pulmonary adenocarcinomas and positive in all 20 malignant mesotheliomas studied. Other workers, however, have reported keratin positivity in appreciable proportion of adenocarcinomas.'22930 Our results show keratin positivity as frequently in adenocarcinomas (12/27) as in malignant mesotheliomas (13/29). The frequency of keratin positivity in our series of malignant mesotheliomas is less than in most other series.8 This could be accounted for in several ways. It is possible that tumour keratin antigenicity might be lost after death so that our postmortem series might be expected to show a lower incidence of positivity than the reported series using surgical pathological specimens. We found no difference, however, in the incidence of keratin positivity between postmortem and surgical cases of adenocarcinoma. Secondly, some workers have reported better results for keratin staining after fixation in ethanol, methanol, or Carnoy's solution.'2 Thirdly, results for keratin positivity could vary because cytokeratins are heterogeneous and different antibodies have different specificities against different cytokeratin polypeptides.3' More work is needed with monoclonal antibodies to determine whether some are more useful than others in differentiating malignant mesothelioma from pulmonary adenocarcinoma. The alcian blue staining technique with and without hyaluronidase was not used with these tumours because we, like others,32 have found that after formalin fixation hyaluronic acid can be demonstrated in less than half of malignant mesotheliomas. The malignant mesotheliomas chosen for this series were typical in gross and light microscopical appearance with little doubt as the the diagnosis. Our study indicates that of the six tumour markers investigated carcinoembryonic antigen and 8, pregnancy specific glycoprotein are the most helpful in the distinction of malignant mesothelioma from pulmonary adenocarcinoma. Carcinoembryonic antigen and the f,3 pregnancy specific glycoprotein were negative in all the malignant mesotheliomas tested whereas one or both were present in all the adenocarcinomas. Thus a positive result for either carcinoembryonic antigen or f,3 pregnancy specific glycoprotein in a tumour is strong evidence against a diagnosis of malignant mesothelioma. A negative result for both carcinoembryonic antigen and f, pregnancy specific glycoprotein is highly suggestive Gibbs, Harach, Wagner, Jasani of malignant mesothelioma if the histological appearances are compatible. Since antibodies to both carcinoembryonic antigen and t3, pregnancy specific glycoprotein are readily available as standardised commercial products, the combined immunolocalisation of carcinoembryonic antigen and the I,3 pregnancy specific glycoprotein should prove an efficient routine means of differentiating lung adenocarcinoma from difficult cases of pleural mesothelioma in both necropsy and surgical cases. We gratefully acknowledge the assistance of Professor ED Williams and Mr ND Thomas, and of Miss J Stitfall for typing the manuscript. References 1 Harwood TR, Gracey DR, Yakoo H. Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer. Am J Clin Pathol 1976; 65: McCaughey WTE, Oldham PD. Diffuse mesotheliomas: observer variation in histological diagnosis. In: Bogovski P, Gilson JC, Timbrell V, Wagner JC, eds. Biological effects ofasbestos. Lyons: International Agency for Research on Cancer, 1973: Wagner JC, Munday DE, Harrington JS. Histochemical demonstration of hyaluronic acid in pleural mesotheliomas. J Pathol Bacteriol 1962;84: Kannerstein M, Churg J, Magner D. Histochemical studies in the diagnosis of mesothelioma. In: Bogovski P, Gilson JC, Timbrell V, Wagner JC, eds. Biological effects of asbestos. Lyons: International Agency for Research on Cancer, 1973: Wang NS. Electron microscopy in the diagnosis of pleural mesotheliomas. Cancer 1973;31: Wang N, Huang S, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancers. Cancer 1979;44: Whitaker D, Sterrett GP, Shilkin KB. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma. Pathology 1982; 14: Corson JM, Pinkus GA. Mesothelioma: Profile of keratin proteins and carcinoembryonic antigen. An immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinoma. Am J Pathol 1982; 108: Said JW, Nash G, Tepper G, Banks-Schlegel S. Keratin proteins and carcinoembryonic antigen in lung carcinoma. Hum Pathol 1983;14: Schlegel R, Banks-Schlegel S, McLeod JA, Pinkus GS. Immunoperoxidase localisation of keratin in human neoplasms. Am J Pathol 1980; 101: Espinoza CG, Azar HA. Immunohistochemical localisation of keratin-type proteins in epithelial neoplasms. Am J Clin Pathol 1982;78: Ramaekers F, Puts J, Maester 0, Kant A, Jap P, Vooijs P. Demonstration of keratin in human adenocarcinoma. Am J Pathol 1983;111: Harach HR, Skinner M, Gibbs AR. Biological markers in human lung carcinoma: an immunopathological study of six antigens. Thorax 1983;38:
5 Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma 14 Pearse AGE. Histochemistry, theoretic and applied. London: Churchill Livingstone, 1971: Jasani B, Wynford-Thomas D, Williams ED. Use of monoclonal antihapten antibodies for immunolocalisation of tissue antigens. J Clin Pathol 1981;34: Jasani B, Thomas ND, Newman GR, Williams ED. DNP-hapten sandwich staining (DHSS) procedure: Design, Sensitivity, Versatility and Applications. Immunol Commun 1983;12: Gibbs AR, Johnston NF, Giddings JC, Jasani B. Primary angiosarcoma of the mediastinum. A light and electron microscopical study with demonstration of Factor VIII related antigen in neoplastic cells. Hum Pathol 1984; 15: Pascal RR, Mesa-Tejada TR, Bennet SJ, Garces A, Fenoglio CM. Carcinoembryonic antigenimmunohistologic identification in invasive and intraepithelial carcinoma of the lung. Arch Pathol Lab Med 1977;101: Walker RA. Biological markers in human breast carcinoma. J Pathol 1982;137: Home CHW, Nisbet AD. Pregnancy proteins: a review. Invest Pathol 1979;2: Gropp C, Haremann K, Scheuer A. Ectopic hormones in lung cancer patients at diagnosis and during therapy. Cancer 1980;46: Rosen SW, Weintraub BD, Vaitukatis JL, Sussmann HH, Hershman JM, Muggier FM. Placental proteins and their subunit as tumour markers. Ann Intern Med 1975;82: Grudzinskas JS, Coombes RC, Ratcliffe JG, Gordon YB, Powles TJ, Munro Neville A, Chard T. Circulating levels of pregnancy specific (3, glycoprotein in patients 95 with testicular, bronchogenic and breast carcinoma. Cancer 1980;45: Wilson TS, McDowell EM, McIntire KR, Trump BF. Elaboration of human chorionic gonadotrophin by lung tumours. Arch Pathol Lab Med 1981;105: Silva OL, Broder LE, Doppman JL, Snider RH, Moore CF, Cohen MH, Becker KL. Calcitonin as a marker for bronchogenic cancer. Cancer 1974;44: Milhaud G, Calmette C, Taboulet J, Julienne A, Markhtar MS. Hypersecretion of calcitonin in neoplastic conditions. Lancet 1974;i: Cooney T, Sweeney EC, Luke D. Pulmonary carcinoid tumours: a comparative regional study. J Clin Pathol 1979;32: Dayal Y, O' Brien DS, Wolfe HJ, Reichlin S. Carcinoid tumours: a comparison of their immunocytochemical hormonal profile with morphologic and histochemical characterisation. Lab Invest 1980;42: 111 (abstract). 29 Walts AE, Said JW, Banks-Schlegel S. Keratin and carcinoembryonic antigen in exfoliated mesothelial and malignant cells. An immunoperoxidase study. Am J Clin Pathol 1983;80: Nagle RB, McDaniel KM, Clark VA, Payne CM. The use of antikeratin antibodies in the diagnosis of human neoplasms. Am J Clin Pathol 1983;79: Muijen GNP, Ruiter DJ, Ponec M, Huiskens-Van May C, Warnaar SO. Monoclonal antibodies with different specificities against cytokeratins. Am J Clin Pathol 1984; 114: Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life-a practical approach. J Pathol 1984; 143:
Practical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
H istochem istry in the Diagnosis o f M alignant M esotheliom a *
A n n a l s o f C l i n i c a l L a b o r a t o r y S c i e n c e, Vol. 3, No. 3 Copyright 1973, Institute for Clinical Science H istochem istry in the Diagnosis o f M alignant M esotheliom a * MILTON
Diagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
Primary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
The develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
Diagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 [email protected]
The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions
The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions Farnaz Hasteh, MD 1 ; Grace Y. Lin, MD, PhD 1 ; Noel Weidner, MD 1 ; and Claire
20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!
Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
The Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas
International Urology and Nephrology 28 (1), pp. 73-77 (1996) Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas $. O. OZDAMAR,*
Cytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
Male. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
How To Test For Cancer
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic
Case of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
Effusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology
Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
Malignant Mesothelioma Electron Microscopy
33 Malignant Mesothelioma Electron Microscopy Raoul Fresco In spite of recent advances in immunocytochemistry, electron microscopy continues to be the gold standard for the differential diagnosis of mesothelioma
How To Diagnose And Treat A Tumour In An Effusion
Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura
BIOBANK LPCE-NICE CHEST
HEST athologist :. BUTORI 08/01/2012 Time for frozen procedure : 45 mn LE / HU Unit atient : N LH 12-2304 N LB 12-0337 onsent : YES Age : 62 ID : MA H Diagnosis and staging : lung adenocarcinoma lymph
HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: [email protected] 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
THE TIMES OF OCCURRENCE OF MESOTHELIOMAS IN RATS FOLLOWING INOCULATION WITH ASBESTOS
582 THE APPLICATION OF A MATHEMATICAL MODEL DESCRIBING THE TIMES OF OCCURRENCE OF MESOTHELIOMAS IN RATS FOLLOWING INOCULATION WITH ASBESTOS G. BERRY AND J. C. WAGNER From the Medical Research Council's
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
Rare Thoracic Tumours
Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC
Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.
Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion
Malaysian J Path01 2002; 24(1) : 53-58 The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion Pavai STHANESHWAR MD, Sook-Fan YAP FRCPath, FRCPA and Gita JAYARAM MDPath, MRCPath
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin)
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin) Product Code: NCL-L-CD141 Leica Biosystems Newcastle Ltd Balliol Business Park West Benton Lane Newcastle Upon Tyne NE12 8EW United Kingdom
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
A 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow ([email protected]) Uma R Chandran ([email protected])
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma MICHAEL G. HURTUK and MICHELE CARBONE Cardinal Bernadin Cancer Center, Cancer Immunology Program, Department of Pathology,
Pathology of lung cancer
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
Uses and Abuses of Pathology in Asbestos-exposed Populations
Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,
Notice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada [email protected] Notice of Faculty Disclosure In accordance with
YOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
Primary malignant gonadal mesotheliomas and asbestos
Histopathology 2000, 37, 150±159 Primary malignant gonadal mesotheliomas and asbestos R L Attanoos & A R Gibbs Department of Histopathology, University Hospital of Wales and Llandough Hospital, Cardiff,
بسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON*
PATTERNS OF MORTALITY IN ASBESTOS FACTORY WORKERS IN LONDON* M. L. Newhouse TUC Centenary Institute of Occupational Health London School of Hygiene and Tropical Medicine London WCIE 7HT. England G. Berry
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
Recommendations for the Reporting of Pleural Mesothelioma
Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports
What is special about a stain, and why do we call some stains
Technical Articles Evolution of Use of Special Stains Alton D. Floyd, PhD Independent Consultant Edwardsburg, MI, USA What is special about a stain, and why do we call some stains special? We all think
Lung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine
Lung Cancer Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Alexandria, Egypt July 1-1 3, 2008 OBJECTIVES Describe and
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
ALTHOUGH excellent accounts have been published in recent years of
THE EXFOLIATIVE CYTOLOGY OF DIFFUSE MALIGNANT MESOTHELIOMA BERNARD NAYLOR Department of Pathology, University of Michigan, Ann Arbor, Michigan, U.S.A. PLATE~ LXXXVI-XCI ALTHOUGH excellent accounts have
Understanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
Distinguishing benign from malignant mesothelial
ORIGINAL ARTICLE IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations Anna F. Lee, MDCM, PhD,*w Allen M. Gown, MD,wz and Andrew Churg, MD*w Abstract:
264 Diagnostic Cytopathology, Vol 38, No 4 ' 2010 WILEY-LISS, INC.
Podoplanin Is a Useful Marker for Identifying Mesothelioma in Malignant Effusions Atef Hanna, M.D., Ph.D., 1 Yijun Pang, M.D., Ph.D., 1 Carlos W. M. Bedrossian, M.D., 2 Annika Dejmek, M.D., Ph.D., 3 and
BIOBANK LPCE-NICE CHEST
BIOBANK LE-NIE HEST athologist : S. LASSALLE 01/03/2011 Time for frozen procedure : 10 mn LE / HU Unit atient : N LH 11-0004 N LB 11-0002 onsent : YES Age : 37 ID : TH ER Diagnosis and staging : Hodgkin
Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany
Services & Products Indivumed GmbH Falkenried 88, Bldg. D 20251 Hamburg Germany Phone Europe: +49-40-41 33 83-0 Fax Europe: +49-40-41 33 83-14 Phone USA: +1-301-588-4650 [email protected] www.indivumed.com
Standards and datasets for reporting cancers. Dataset for the histological reporting of mesothelioma. April 2013
Standards and datasets for reporting cancers Dataset for the histological reporting of mesothelioma April 2013 Authors Professor Andrew G Nicholson, Royal Brompton Hospital and Harefield NHS Trust Professor
3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
ATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA
Papillary carcinoma is the most common of thyroid malignancies and occurs in all age groups but particularly in women under 45 years of age. There is a high rate of cervical metastatic disease and yet
Product Datasheet and Instructions for Use
Product Code: MP-378-CMK01 (0.1ml conc) MP-378-CMK05 (0.5ml conc) MP-378-PM6 (6ml RTU) Product Description: CD141 (Thrombomodulin) Concentrated and Prediluted Monoclonal Antibody Control Number: 901-378-071709
Cytopathology of Pleural Mesotheliomas
Cytopathology of Pleural Mesotheliomas Gia-Khanh Nguyen, MD Key Words: Pleural mesothelioma; Epithelial mesothelioma; Sarcomatous mesothelioma; Mixed mesothelioma; Exfoliative cytology; Fineneedle aspiration
Malignant mesothelioma: incidence, asbestos
British Journal of Industrial Medicine 1984;41: 39-45 Malignant mesothelioma: incidence, asbestos exposure, and reclassification of histopathology W E WRIGHT,' R P SHERWIN,2 ELIZABETH A DICKSON,' L BERNSTEIN,'
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014
Materials and Methods Specimens
The Expression Pattern of b-catenin in Mesothelial Proliferative Lesions and Its Diagnostic Utilities Yiran Dai, M.D., 1 * Carlos W.M. Bedrossian, M.D., FIAC, 2 and Claire W. Michael, M.D. 1 b-catenin
BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA
BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA 1 CUTTING-EDGE ISSUES IN ASBESTOS LITIGATION CONFERENCE Scott Masterson Lewis, Brisbois, Bisgaard & Smith, LLP 1180 Peachtree Street, NE, Suite 2900
Diseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours
Pleura Visceral pleura covers lungs and extends into fissures Parietal pleura limits mediastinum and covers dome of diaphragm and inner aspect of chest wall. Two layers between them (pleural cavity) contains
New marker for mesothelioma: an
J Clin Pathol 1986;39:961-968 New marker for mesothelioma: an immunoperoxidase study A DONNA, P G BETTA, D BELLINGERI, A MARCHESINI* From the Department of Pathology, City Hospital, Alessandria, Italy,
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
BIOBANK LPCE-NICE CHEST
BIOBANK LE-NIE HEST athologist :. BUTORI 12/09/2013 LE / HU Unit atient : N LH13-3603 N LB 13-0691 ID : RO A onsent : YES Age : 54 Diagnosis and staging : chronic pleuresia 5x1000µL BIOBANK LE-NIE HEST
Role of immunohistochemistry
Tumors of serous membranes of difficult diagnosis: Dr. Hector Battifora Role of immunohistochemistry Abstract: The most common differential diagnosis of tumors involving serosal surfaces is adenocarcinoma
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the
between occupations and asbestos-fibre content of the lungs in patients with pleural
Thorax, 1977, 32, 377-386 Relationship between occupations and asbestosfibre content of the lungs in patients with pleural mesothelioma, lung cancer, and other diseases F. WHITWELL, JEAN SCOTT, AND MYRA
Malignant Mesothelioma in Urban Dogs
Vet. Pathol. 20: 53 1-540 (I 983) Malignant Mesothelioma in Urban Dogs M. L. HARBISON and J. J. GODLESKI Department of Pathology, Harvard Medical School, Angel1 Memorial Animal Hospital, Brigham and Women
Avastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
Diagnosis of Lung Cancer in Small Biopsies and Cytology
Diagnosis of Lung Cancer in Small Biopsies and Cytology Implications of the 2011 International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society Classification
Lymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma
Anatomic Pathology / LYMPHOHISTIOCYTOID MESOTHELIOMA Lymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma Hasan S. Khalidi, MD, 1 L. Jeffrey Medeiros, MD,
Colon cancer and normal cell lines
The Essentials of Life Science Research Globally Delivered Colon cancer and normal cell lines ATCC No. Name Tissue Cell Type Disease Oganism Age Ethnicity Genes Expressed CRL-2577 RKO Carcinoma CRL-2579
